Access to Biomarker Testing

Share

Biomarker testing is key to unlocking precision medicine.

Biomarkers are often used to help determine the best treatment for a patient, but not all communities are benefitting from the latest advancements in biomarker testing and precision medicine.


Progress in improving cancer outcomes increasingly involves the use of precision medicine. Biomarker testing is an important step for accessing precision medicine including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients. But without action to expand coverage of and access to biomarker testing, advances in precision medicine could increase existing disparities in cancer outcomes by race, ethnicity, income, and geography.

ACS CAN is working to expand insurance coverage of comprehensive biomarker testing. 

Map of biomarker testing coverage legislation

Legislation introduced: CA, MN, NY, OH, WA
Legislation passed: AZ, IL, LA, RI

Get more information about our campaigns.

California | New York | Texas

Biomarker testing helps ensure cancer patients get the right treatment at the right time.

It allows doctors to precisely target a specific cancer so patients may not have to undergo more generalized treatments like chemo and radiation that may not work as well for them.

Patient and Provider Stories

Heather

Heather’s Story

Pete

Pete’s Story

Ruth

Ruth’s Story

Carla

Carla’s Story

 

Take Action

Researcher

Help cancer patients get the right treatment at the right time!

Biomarker testing is the latest advanced in cancer research that is personal to the patient and their cancer, helping ensure patients get the right treatment at the right time. 

Latest Updates

January 31, 2023
Georgia

ATLANTA, GA – January 31, 2023 – Today, Rep. Sharon Cooper filed a bill (HB85) that will allow more Georgians to receive biomarker testing – a routine step in accessing personalized medicine treatments that has become an increasingly important part of cancer care in recent

January 19, 2023
New York

ALBANY, NY – JANUARY 19, 2023 – Last week the American Cancer Society (ACS) released their annual report “Cancer Facts and Figures” projecting cancer’s impact in 2023. Released in time for Cervical Cancer Awareness Month, the 2023 report estimates that around 850 New Yorkers will be diagnosed with cervical cancer

January 18, 2023
Pennsylvania

PHILADELPHIA, PA – JANUARY 18, 2023 – Last week the American Cancer Society (ACS) released their annual report “Cancer Facts and Figures” projecting cancer’s impact in 2023. Released in time for Cervical Cancer Awareness Month, the 2023 report estimates that around 510 Pennsylvanians will be diagnosed with cervical cancer and

January 9, 2023
Washington

OLYMPIA, WA. – As lawmakers dive into the 2023 legislative session, the American Cancer Society Cancer Action Network (ACS CAN) urges state lawmakers to prioritize legislation that ensures biomarker testing is appropriately covered by more insurance plans, including Apple Health, which will ease the burden of cancer on Washington residents.

Access to Biomarker Testing Resources

Biomarker testing is becoming increasingly important for cancer care because it connects the right patient, to the right treatment, at the right time, however insurance coverage of testing varies widely.

ACS CAN conducted a survey of 315 oncology providers examining barriers providers face in performing recommended cancer biomarker testing. The survey found that providers face challenges such as lab turnaround time, patient concerns about out-of-pocket-costs, and insurance coverage of biomarker tests.

Precision medicine in cancer involves targeted therapies which work by interfering with specific cellular processes involved in the growth, spread, and progression of cancer. Treatment with targeted therapy often requires diagnostic testing to identify specific cancer biomarkers. Testing patients for biomarkers is integral to precision medicine in cancer care.